Literature DB >> 23053334

[Corneal ulcer caused by MRSA after UV/riboflavin cross-linking in a patient with bilateral keratoconus].

M Bödemann1, T Kohnen.   

Abstract

Riboflavin/UV cross-linking is a surgical method for stabilizing a progressive form of keratoconus which was developed in Germany and is now used worldwide. The procedure is considered to be safe and rarely results in complications. In this article we report the case of a 40-year-old male patient with a severe infection due to methicillin-resistant Staphylococcus aureus (MRSA) after uneventful cross-linking in the better eye. Despite intensive local and oral therapy the ulcer did not heal completely and penetrating keratoplasty had to be performed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053334     DOI: 10.1007/s00347-012-2603-2

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  9 in total

1.  Severe keratitis following corneal cross-linking for keratoconus.

Authors:  Paolo Rama; Federico Di Matteo; Stanislav Matuska; Chiara Insacco; Giorgio Paganoni
Journal:  Acta Ophthalmol       Date:  2010-11-25       Impact factor: 3.761

2.  Bacterial keratitis early after corneal crosslinking with riboflavin and ultraviolet-A.

Authors:  Matthias Pollhammer; Claus Cursiefen
Journal:  J Cataract Refract Surg       Date:  2009-03       Impact factor: 3.351

3.  [Corneal crosslinking: "Safe and effective"?].

Authors:  C Cursiefen
Journal:  Ophthalmologe       Date:  2009-02       Impact factor: 1.059

4.  Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study.

Authors:  Aldo Caporossi; Cosimo Mazzotta; Stefano Baiocchi; Tomaso Caporossi
Journal:  Am J Ophthalmol       Date:  2010-02-06       Impact factor: 5.258

Review 5.  Pseudomonas keratitis after collagen crosslinking for keratoconus: case report and review of literature.

Authors:  Namrata Sharma; Praful Maharana; Gurnarinder Singh; Jeewan S Titiyal
Journal:  J Cataract Refract Surg       Date:  2010-03       Impact factor: 3.351

6.  Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus.

Authors:  Gregor Wollensak; Eberhard Spoerl; Theo Seiler
Journal:  Am J Ophthalmol       Date:  2003-05       Impact factor: 5.258

7.  Changes in rotation after implantation of a bag-in-the-lens intraocular lens.

Authors:  Jos J Rozema; Laure Gobin; Kristien Verbruggen; Marie-José Tassignon
Journal:  J Cataract Refract Surg       Date:  2009-08       Impact factor: 3.351

8.  [Collagen cross-linking with riboflavin and UVA light in keratoconus. Results from Dresden].

Authors:  A Hoyer; F Raiskup-Wolf; E Spörl; L E Pillunat
Journal:  Ophthalmologe       Date:  2009-02       Impact factor: 1.059

9.  Corneal melting after collagen cross-linking for keratoconus: a case report.

Authors:  Georgios Labiris; Eleni Kaloghianni; Stavrenia Koukoula; Athanassios Zissimopoulos; Vassilios P Kozobolis
Journal:  J Med Case Rep       Date:  2011-04-16
  9 in total
  4 in total

1.  [Corneal collagen cross-linking with riboflavin and ultraviolet-A light in progressive keratoconus. Results after 10-year follow-up].

Authors:  A Theuring; E Spoerl; L E Pillunat; F Raiskup
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

2.  [Riboflavin UVA cross-linking for keratoconus].

Authors:  P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

3.  Infectious keratitis after corneal crosslinking: systematic review.

Authors:  Caroline E Murchison; W Matthew Petroll; Danielle M Robertson
Journal:  J Cataract Refract Surg       Date:  2021-08-01       Impact factor: 3.528

4.  Methicillin-Resistant Staphylococcus aureus Ocular Infection after Corneal Cross-Linking for Keratoconus: Potential Association with Atopic Dermatitis.

Authors:  Romina Fasciani; Antonio Agresta; Alice Caristia; Luigi Mosca; Andrea Scupola; Aldo Caporossi
Journal:  Case Rep Ophthalmol Med       Date:  2015-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.